Biovascular biovascularinc.com


Public lists: Pharma Startups (4732)

BioVascular Inc. is a privately held biotechnology company that develops drugs and devices for the control of intimal hyperplasia associated with vascular procedures and control of risk factors associated with cardiovascular morbidity and mortality. BioVascular's lead product, saratin, is a polypeptide produced by recombinant means in yeast. This product was licensed from Merck, KGaA in 2005. BioVascular began human clinical trials of saratin for hemodialysis graft access in late 2006 and will...Show all

BioVascular Inc. is a privately held biotechnology company that develops drugs and devices for the control of intimal hyperplasia associated with vascular procedures and control of risk factors associated with cardiovascular morbidity and mortality. ...Show all

Company (Alive / Active)

Phone: 858-455-5000

Fax:

12230 El Camino Real
Suite 100
San Diego, 92130
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Biovascular $10.9M Feb 22, 2008
See all 21 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Biovascular Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 5 investors

Competitors

Company Status Description Investors

Protalex

New Hope, Pennsylvania, United States
IPO / Went publicProtalex (www.protalex.com) is a biotechnology company engaged in the development of a new class of immunomodulatory drugs for treatment of rheumatoid arthritis and other autoimmune diseases. The company takes a unique approach towards autoimmune diseases as its drugs act upon cells at the primitive level of function. The company will enter Phase I clinical trials within the next year for its first drug that addresses Rheumatoid Arthritis. Pre-clinical studies in Lupus and Chron's disease are se...Show allLogin to see details

Can-Fite Biopharma

Israel
Alive / ActiveCan-Fite is an Israeli science-based biopharmaceutical company with the mission to develop treatments for autoimmune diseases and cancer. The company's drugs which piggyback on a natural mechanism, are small molecules, orally administered, induce specific activity towards their target pathological cells and demonstrated an excellent safety profile in human clinical studies.Login to see details
See all 21 competitors